Douglas W Losordo

US Patent:

20070173471, Jul 26, 2007

Filed:

Jan 24, 2006

Appl. No.:

11/339808

Inventors:

Douglas Losordo - Boston MA, US

International Classification:

A61K 48/00
A61K 38/17
A61F 2/02

US Classification:

514044000, 424423000, 514012000

Abstract:

Disclosed are compositions and methods for preventing, treating, or reducing symptoms associated with a myocardial or related disorder such as an infarction. In one embodiment, the method includes administering a therapeutically effective amount of a nucleic acid encoding at least one morphogen; or an effective fragment thereof. Preferred morphogens include the human Sonic Hedghog (Shh), human Desert Hedgehog (Dhh), and human Indian Hedgehog (Ihh) proteins. The methods can be used alone or in combination with other methods involving administration of an angiogenic protein, hematopoietic protein, or endothelial precursor cells (EPCs).

US Patent:

20100028312, Feb 4, 2010

Filed:

Mar 24, 2006

Appl. No.:

11/887021

Inventors:

Ryuichi Aikawa - Brookline MA, US
Douglas W. Losordo - Chicago IL, US

Assignee:

Caritas St. Elizabeth Medical Center of Boston Inc - Boston MA

International Classification:

A61K 35/12

US Classification:

424 9321

Abstract:

The invention provides compositions comprising genetically modified bone marrow cells and related therapeutic and diagnostic methods. Transduced bone marrow cells can be therapeutically administered to a subject, such as a human patient to provide for the expression of an encoded protein in the subject in need thereof.

US Patent:

20130101628, Apr 25, 2013

Filed:

Apr 29, 2012

Appl. No.:

13/459234

Inventors:

Matthew J. Webber - Cambridge MA, US
Jörn Tongers - Hannover, DE
Douglas W. Losordo - Chicago IL, US
Samuel I. Stupp - Chicago IL, US

Assignee:

NORTHWESTERN UNIVERSITY - Evanston IL

International Classification:

C07K 14/00

US Classification:

424400, 530300, 530326, 514 133

Abstract:

Disclosed herein is a completely synthetic cell-free therapy based on peptide amphiphile nanostructures designed to mimic the activity of vascular endothelial growth factor (VEGF), one of the most potent angiogenic signaling proteins. The VEGF-mimetic filaments disclosed herein were found to induce phosphorylation of VEGF receptors and induce pro-angiogenic behavior in endothelial cells, indicated by an enhancement in proliferation, survival and migration in vitro.